A leading gene therapy manufacturer was considering a new business model for their patented gene editing technology platform and sought guidance on potential demand and the associated capabilities required, as well as an analysis of what conditions and international markets would be most attractive.
Marwood found modest demand for the proposed business model and identified potential areas of refinement to expand interest. Based on the cost of therapy manufacturing using the Company’s proprietary technology, only certain high-cost therapies appeared financially attractive. The US, and a number of markets in the EU and Asia, were identified as particularly favorable for this model based on regulatory and reimbursement dynamics.
A national, behavioral health-focused managed care company engaged Marwood to provide strategic assessment of telemedicine and virtual/digital cognitive behavioral health market players to ultimately incorporate within the plan’s broader digital health strategy as a partner. The Company’s business lines had separately explored six different digital solution vendors and partnerships, though most had low engagement.
Together with Marwood, the Company outlined key focus areas for a successful digital experience, built from various components, leveraging internal strengths, external acquisitions, and close collaborations. Marwood’s analysis of current coverage of the components of the Company’s digital experience revealed a limited current coverage level, with gaps and areas for improvement. Marwood profiled 83 potential digital solutions vendors and built identifiable profiles outlining the key strengths, weaknesses, and characteristics and matched these vendors up to the selection criteria outlined by Marwood and Company as defined by the end goal digital experience.